Theravance Biopharma R&D IP, LLC et al v. Lupin Inc. et al
| Theravance Biopharma R&D IP, LLC, Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Ireland Limited and Mylan Specialty L.P. |
| Lupin Inc., Lupin Ltd. and Lupin Pharmaceuticals, Inc. |
| 1:2023cv00187 |
| February 17, 2023 |
| US District Court for the District of Delaware |
| Gregory B Williams |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 28, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 8 Report to the Commissioner of Patents and Trademarks. (ntl) |
| Filing 7 NOTICE of Voluntary Dismissal by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc. (Bourke, Mary) |
| CASE CLOSED (ntl) |
| Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris, Inc. for Mylan Ireland Limited, Mylan Specialty L.P. filed by Mylan Ireland Limited, Mylan Specialty L.P.. (Stamoulis, Stamatios) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Theravance Biopharma, Inc. for Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, and Theravance Biopharma US, Inc. filed by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc.. (mpb) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531. (mpb) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/12/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/9/2026. (mpb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Filing 1 COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Civil Cover Sheet)(mpb) |
| DEFICIENCY NOTICE issued by the Court to Plaintiffs Mylan Ireland Limited and Mylan Specialty L.P.: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (mpb) |
| No Summons Issued. (mpb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
